Merck and Schering-Plough end j-v for Claritin/Singulair combo
This article was originally published in Scrip
Executive Summary
Merck & Coand Schering-Ploughhave withdrawn their US new drug application for a fixed-dose combination product containing loratadine and montelukast for allergic rhinitis patients who want relief from nasal congestion, ending an eight-year joint effort on the respiratory drugs.